Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/06/2003US20030206956 Topical treatment of prevention of ocular infections
11/06/2003US20030206955 Oil-in-water; nonionic and/or anionic amphiphilic lipid; anionic polymer which contains at least one hydrophobic chain; weight ratio of the amount of oily phase to the amount of amphiphilic lipid ranges from 1.2 to 10.
11/06/2003US20030206954 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
11/06/2003US20030206952 In a matrix with a hydrophilic polymer that is high molecular weight polyethylene oxide, hydroxypropylmethyl cellulose, or hydroxypropyl cellulose.
11/06/2003US20030206951 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
11/06/2003US20030206947 Low viscosity hydroxypropylcellulose with an average molecular weight of 30,000-100,000 and with a molar degree of substitution of at least 3
11/06/2003US20030206946 Methods for therapy of connective tissue disease
11/06/2003US20030206942 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
11/06/2003US20030206941 Fast dissolving orally consumable films
11/06/2003US20030206936 Cosmetic composition and method of treating skin and hair
11/06/2003US20030206935 P-(alpha-hydroxyhydrocarbylcarbonylamino)-substituted benzoic acid esters; reducing and/or slowing down the loss of head hair and/or body hair, or inducing and/or stimulating its growth.
11/06/2003US20030206933 Treatment of keratin fibers and skin.
11/06/2003US20030206930 Soft gelatin capsule manufacture
11/06/2003US20030206929 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides
11/06/2003US20030206923 Combination of soybean, mushroom and mung bean provides phytoestrogens, beta-glucans, saponins, inositol hexaphosphate, and lectins.
11/06/2003US20030206911 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target
11/06/2003US20030206906 Water, a plasminogen activator, and a bacteriostatic organic alcohol preservative; does not contain a chelating agent; removal of fibrin-bound blood clots from a catheter
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206896 Topically applying to the skin a protease enzyme, and simultaneously or sequentially, topically applying to the skin a polyhydric alcohol.
11/06/2003US20030206895 L-carnitine or an alkanoyl derivative or salt; flavonoid may be quercetin, rutin, myricetin or myricitrin.
11/06/2003US20030206893 Cell proliferating agents
11/06/2003US20030206885 Vaccine immunotherapy for immune suppressed patients
11/06/2003US20030206882 Ready-to-use teat dip also containing a sulfonate or sulfate hydrotrope solubilizer; mineral acid-free
11/06/2003US20030206875 Compositions for treating biofilm
11/06/2003US20030206874 Promoting whole body health
11/06/2003US20030206873 1,4-di(substituted phenyl)- derivatives; adapted for delayed release
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206868 Immune response modifier compounds for treatment of th2 mediated and related diseases
11/06/2003US20030206867 Spray that delivers unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means.
11/06/2003US20030206866 1,2,3,6-Tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003US20030206858 Metal complex-containing pharmaceutical agents
11/06/2003US20030205229 Drug delivery apparatus
11/06/2003DE20313224U1 Synergistic composition for treating metabolic syndrome, comprises swellable or gel-forming anorectic agent for inducing satiation and polymeric or other hypocholesterolemic and/or antidiabetic agent
11/06/2003CA2496454A1 Transdermal analgesic systems with reduced abuse potential
11/06/2003CA2487245A1 An injection made from ixeris sonchifolia hance for treatment of cardio-cerebral vascular diseases and fundus diseases and method of producing thereof
11/06/2003CA2484546A1 Methods and compositions for treatment of cancer pain
11/06/2003CA2484453A1 Medicinal compositions containing photocrosslinkable chitosan derivative
11/06/2003CA2484306A1 Prophylactic and therapeutic agent of diabetes mellitus
11/06/2003CA2484090A1 Nitrosated imidazopyridines
11/06/2003CA2484089A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
11/06/2003CA2484079A1 Expression systems for stem-loop rna molecule having rnai effect
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483725A1 Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin
11/06/2003CA2483636A1 3,4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003CA2483557A1 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/06/2003CA2483554A1 Treatment of hypertension in women receiving hormone replacement therapy
11/06/2003CA2483530A1 Quinazoline derivatives and medicaments
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483449A1 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
11/06/2003CA2483340A1 Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
11/06/2003CA2483336A1 Method and apparatus for ultrasound treatment of connective tissue
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483306A1 Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
11/06/2003CA2483281A1 11-deoxy azalide antibacterials
11/06/2003CA2483265A1 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003CA2483263A1 Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483221A1 9-oxime macrolide antibacterials
11/06/2003CA2483220A1 Oxolide antibacterials
11/06/2003CA2483203A1 Hyperforin halogenated derivatives, the use thereof and formulations containing them
11/06/2003CA2483155A1 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
11/06/2003CA2483103A1 Pharmaceutical composition containing lamotrigine particles of defined morphology
11/06/2003CA2483093A1 Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
11/06/2003CA2483092A1 Tolterodine salts
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2483005A1 Treatment of metabolic syndrome
11/06/2003CA2482996A1 Vitamin d3 upregulated protein 1 treats post-infarct myocardial ischemia
11/06/2003CA2482941A1 Microparticle pharmaceutical compositions for intratumoral delivery
11/06/2003CA2482936A1 Capsule preparation
11/06/2003CA2482711A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2482432A1 Method of preparing amine stereoisomers
11/06/2003CA2482019A1 Use of conjugated linoleic acid or derivative thereof in the treatment of influenza
11/06/2003CA2481449A1 Method and compositions for identifying anti-hiv therapeutic compounds
11/06/2003CA2481324A1 [1,4]diazocino [7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents
11/06/2003CA2481285A1 Non nucleoside reverse transcriptase inhibitors
11/06/2003CA2481215A1 Compositions comprising protein and fatty acid and processes of their preparation
11/06/2003CA2481213A1 Compositions comprising milk protein concentrate and fatty acid and processes of their preparation
11/06/2003CA2481209A1 Acidic compositions comprising protein and fiber and processes of their preparation
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480293A1 New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2480130A1 Method for producing crystals from active ingredients in medicaments and the use thereof in pharmaceutical formulations
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2479992A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
11/06/2003CA2479943A1 Method for reduction of residual organic solvent in carbomer
11/06/2003CA2454612A1 Ultrasonic doppler effect speed measurement
11/05/2003EP1359215A1 Soya cell strains with high isoflavone content
11/05/2003EP1359154A1 Further syntheses of cyproterone acetate
11/05/2003EP1359152A2 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
11/05/2003EP1359147A1 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same
11/05/2003EP1359146A2 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
11/05/2003EP1358909A1 Heteroaryl-phenyl derivatives as factor xa inhibitors for use as antithrombotic and anticoagulant agents
11/05/2003EP1358889A1 Medicinal compositions for treating lower uropathy
1 ... 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 5296 5297 5298 5299 5300 5301 5302 5303 5304 5305 5306 ... 7860